TY - JOUR
T1 - A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]
AU - Ahn, Eric
AU - Pairaudeau, Nicholas
AU - Cérat, Yves
AU - Couturier, Bernard
AU - Fortier, Andre
AU - Paradis, Éric
AU - Koren, Gideon
PY - 2006/4/4
Y1 - 2006/4/4
N2 - Background: Prenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms. This coupled with nausea and vomiting of pregnancy results in women often discontinuing their multivitamins. A new prescription supplement (PregVit®) that separates iron from calcium in two tablets - morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®). The objectives of this study were to compare tolerability and compliance with PregVit® vs. a supplement with high iron content (Materna®), in pregnant women. Methods: Randomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec. Results: Use of PregVit® was associated with a 30% reduction in constipation rate as compared to Materna®. Both products demonstrated similar compliance rates. Compliance of Materna® was negatively associated with the severity of nausea and vomiting of pregnancy. No such correlation was found for PregVvit®. Conclusion: PregVit®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates. High iron content in multivitamin supplements is associated with adverse effects in pregnancy.
AB - Background: Prenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms. This coupled with nausea and vomiting of pregnancy results in women often discontinuing their multivitamins. A new prescription supplement (PregVit®) that separates iron from calcium in two tablets - morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®). The objectives of this study were to compare tolerability and compliance with PregVit® vs. a supplement with high iron content (Materna®), in pregnant women. Methods: Randomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec. Results: Use of PregVit® was associated with a 30% reduction in constipation rate as compared to Materna®. Both products demonstrated similar compliance rates. Compliance of Materna® was negatively associated with the severity of nausea and vomiting of pregnancy. No such correlation was found for PregVvit®. Conclusion: PregVit®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates. High iron content in multivitamin supplements is associated with adverse effects in pregnancy.
UR - http://www.scopus.com/inward/record.url?scp=33745453038&partnerID=8YFLogxK
U2 - 10.1186/1471-2393-6-10
DO - 10.1186/1471-2393-6-10
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:33745453038
SN - 1471-2393
VL - 6
JO - BMC Pregnancy and Childbirth
JF - BMC Pregnancy and Childbirth
M1 - 10
ER -